+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand



Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand



Journal of Infectious Diseases 180(4): 1282-1287



WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n=15) received 300 mg daily for 7 days; group B (n=11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n=9), 1 dose of 500 mg. A fourth group (D; n=9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n=23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 003540756

Download citation: RISBibTeXText

PMID: 10479159

DOI: 10.1086/315034


Related references

Randomized Dose-Ranging Study of the Safety and Efficacy of Wr 238605 (Tafenoquine) in the Prevention of Relapse of Plasmodium vivax Malaria in Thailand. The Journal of Infectious Diseases 180(4): 1282-1287, 1999

Dose-ranging study of the safety and efficacy of WR 238605 in the prevention of relapse of Plasmodium vivax malaria in Thailand. American Journal of Tropical Medicine & Hygiene 61(3 Suppl. ): 279, 1999

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clinical Infectious Diseases 39(8): 1095-1103, 2004

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383(9922): 1049-1058, 2014

Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(3): 215-228, 2019

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. Plos one 12(11): E0187376, 2017

Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. American Journal of Tropical Medicine and Hygiene 69(5): 542-547, 2003

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Design Development and Therapy 10: 2387-2399, 2016

Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. Infection and Drug Resistance 12: 553-570, 2019

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2015(4): Cd010458, 2015

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(19): 1875, 2019

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(3): 229-241, 2019

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clinical Infectious Diseases 33(12): 1968-1974, 2001

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malaria Journal 15: 97, 2016

Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. Journal of Infectious Diseases 190(8): 1456-1463, 2004